Key result
In adjuvant-inflamed rats, the cutaneous blood flow increase response to sympathetic nerve stimulation was significantly reduced by an alpha1-adrenoceptor antagonist but not by alpha2- or beta-adrenoceptor antagonists.
p-value: p=<0.05
The cutaneous blood flow increase in response to sympathetic stimulation in inflamed rats involves a non-adrenergic mechanism in addition to noradrenaline.
Sympathetic vasomotor reversal in inflamed skin remains preclinical; leaves open mechanisms and human translation pending higher-level studies.
There is some evidence that the sympathetic nervous system plays a role in the development and/or maintenance of painful states, and that sympathetic nervous function is altered in these conditions. Our previous experiments showed that electrical stimulation of the lumbar sympathetic trunk (sympathetic stimulation: SS), which normally induces a decrease in blood flow (BF) of plantar skin, induced its BF increase in about 50% of adjuvant-inflamed rats. To investigate the mechanism of this BF-increase response, we examined whether noradrenaline (NA) plays any role in this changed response to SS, and which receptor subtype is involved. We measured paw cutaneous BF response with a laser Doppler flowmeter in rats chronically inflamed with complete Freund's adjuvant. SS induced the BF-increase response in 50-67% of measured sites. Close-arterially injected NA induced the BF-increase response at dosages between 10-100 ng/kg only at the sites with the BF-increase response to SS. The BF-increase and -decrease responses to NA was significantly reduced after the close-arterial injection of either alpha1- or alpha2-adrenoceptor antagonists (p lt; 0.05, respectively). In contrast, although the BF-decrease responses to SS were significantly reduced by administration of alpha1- and alpha2-adrenoceptor antagonist, BF-increase response was reduced only by alpha1-adrenoceptor antagonist, and that only at a higher dose. In addition, the beta-adrenoceptor antagonist had no effects on both responses. These results suggest that the BF-increase response to SS involves, additionally to NA, a non-adrenergic mechanism.
No takes yet. Share an insight, caveat, or question.
Koeda et al. (2002) studied Persistent inflammation (n=58). Adrenoceptor antagonists (prazosin, CH-38083) vs. Baseline (before administration) was evaluated on Reduction in blood flow-increase response to sympathetic stimulation (p=<0.05). In adjuvant-inflamed rats, the cutaneous blood flow increase response to sympathetic nerve stimulation was significantly reduced by an alpha1-adrenoceptor antagonist but not by alpha2- or beta-adrenoceptor antagonists.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: